T1	Participants 44 67	migraine in adolescents
T2	Participants 170 224	efficacy of rizatriptan 5 mg in adolescent migraineurs
T3	Participants 286 371	Patients aged 12 to 17 years received rizatriptan 5 mg (n = 149) or placebo (n = 147)
T4	Participants 802 838	among patients receiving rizatriptan
T5	Participants 908 1007	The percentage of patients pain-free at 2 hours was 32% for rizatriptan 5 mg versus 28% for placebo
T6	Participants 1018 1173	The percentage of patients with pain relief (reduction of predose pain intensity to mild or none) at 2 hours was 66% for rizatriptan versus 56% for placebo
T7	Participants 1252 1293	previous studies of rizatriptan in adults
T8	Participants 1503 1552	in the percentage of patients who had pain relief
T9	Participants 1704 1752	response rate was similar to that seen in adults
T10	Participants 1806 1896	effective on some measures when used in adolescents for the treatment of a migraine attack
